Oncorus Raises $79.5m To Take Its First Oncolytic Virus Into The Clinic
Executive Summary
The company has two oncolytic virus platforms – a herpes simplex-based intratumoral injection and a synthetic virus-based intravenous technology for repeat systemic administration.
You may also be interested in...
IPO Update: 58 Drug Developers Raised $12.5bn Through Q3
The average return for companies that went public in the US through the end of September was 49.4% as of 5 October. The fourth quarter started with three additional initial public offerings on 1 October.
Finance Watch: Kymera Will Start Protein Degrader Clinical Trials With $102m VC Round
Private Company Edition: Kymera said it will take up to three programs into the clinic by next year. Also, three new life science funds recently launched, including a Gates Foundation-backed accelerator for COVID-19 treatments, and Cell Medica reemerges as Kuur with new funding for CAR-NKT therapies.
Finance Watch: Deerfield Invests $635m In New York Start-Ups, Pledges $2bn Globally By 2030
Private Company Edition: Deerfield is funding a new life science campus. Also, BioFractura gets up to $67.4m in BARDA contract in recent grant and government deal surge, Mission Bay raises a $60m fund and Amphivena closes a $62m VC round.